About
Detects Alzheimer's-associated amyloid from a hyperspectral eye scan; commercialising via research/memory-clinic programs. Backed by Eli Lilly, Topcon Healthcare, ADDF.
HQ: Toronto, Canada
Funding
$10M Series A (Jul 2024); $17M total
—Company profile
Hyperspectral retinal imaging + AI to detect Alzheimer's-associated amyloid from an eye exam.
Detects Alzheimer's-associated amyloid from a hyperspectral eye scan; commercialising via research/memory-clinic programs. Backed by Eli Lilly, Topcon Healthcare, ADDF.
HQ: Toronto, Canada